Alloy Therapeutics

What Alloy Therapeutics does

Alloy Therapeutics is a privately held biotechnology platform company founded in 2017 and headquartered in Waltham, Massachusetts. The company provides integrated drug discovery infrastructure across multiple therapeutic modalities — antibodies, bispecifics, TCR mimics, antisense oligonucleotides, and cell therapies — to biopharmaceutical partners ranging from large pharma (Pfizer, AbbVie, Sanofi, Takeda, Biogen) to mid-market biotech, startups, academic institutions, and government/sovereign customers. Its flagship ATX-Gx transgenic mouse platform (ATX-GK, ATX-GL, ATX-GKH, ATX-CLC strains) underpins fully human antibody discovery and is licensed to 200+ partners, with 10+ partner-discovered antibodies in clinical development. The platform is augmented by Keyway TCRm discovery, AntiClastic cyclic antisense RNA architecture, iPSC-derived iCAR-T cell therapy (originating from the Takeda-CiRA program), and the mAbForge high-throughput screening and AI/ML infrastructure (Deep Repertoire Intelligence, ACE, SmartSelect, predictive developability). Discovery services can deliver qualified leads in approximately 4 months.

The company monetizes through a hybrid model: platform licensing (restructured in January 2025 to eliminate annual access fees), fee-for-service discovery campaigns, milestone payments (the Sanofi AntiClastic collaboration carries potential milestones exceeding $400M plus tiered royalties), tiered royalties on partnered products, and equity stakes in asset-centric companies created through its 82VS venture studio. The company reinvests 100% of profits into platform R&D and has expanded globally to Cambridge UK (transgenic platform), Basel (computational biology), Athens GA (antibody discovery), Shonan iPark Japan (cell therapies), and Ontario Canada. Through April 2026, Alloy has raised approximately $168M+ in venture funding across Series C, D, and E rounds and reached a $1 billion valuation. Recent strategic moves include the October 2025 acquisition of Spannerwerks (drug development), launch of the Vigilance Division for AI-driven biosecurity, and major pharma collaborations with AbbVie, Pfizer, Sanofi, and Biogen. The company supports 100+ licensed therapeutic programs with 22 in clinical development including two in Phase 3 trials.

Name

Alloy Therapeutics

Legal name

Alloy Therapeutics, Inc.

Website

https://alloytx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Alloy Therapeutics is a biotechnology platform company that licenses proprietary transgenic mouse, antisense oligonucleotide, TCR mimic, and cell therapy discovery technologies to 200+ biopharma and academic partners. It combines AI/ML-enabled services, fee-for-service campaigns, milestone/royalty deals, and its 82VS venture studio.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), CAR-T & TCR-T Therapies (HLAAABAC), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Antibody discovery platforms
• Drug discovery services
• Transgenic mouse platforms
• Biologics research
• Therapeutic development

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform Licensing: Licensing of proprietary technology platforms (ATX-Gx transgenic mice, AntiClastic ASO platform, Keyway TCRm) to biopharma partners. In January 2025, Alloy changed its licensing model to eliminate annual access fees and development milestones, democratizing access to foundational discovery technologies.
2. Discovery Services: Fee-for-service discovery campaigns providing end-to-end antibody discovery, bispecific engineering, TCRm discovery, and genetic medicine development services to partners.
3. Milestone Payments: Preclinical, development, and commercial milestone payments from pharmaceutical partners. Examples include Sanofi collaboration with potential milestones exceeding $400M plus tiered royalties.
4. Royalties: Tiered royalties on product sales resulting from partnered programs utilizing Alloy's platforms and technologies.
5. Venture Studio (82VS): Company-creation business model through 82VS venture studio, establishing asset-centric drug companies leveraging Alloy's platforms with equity stakes in portfolio companies.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Alloy Therapeutics is a biotechnology ecosystem company that provides an integrated platform of drug discovery technologies and services across multiple therapeutic modalities, including antibodies, bispecifics, TCR mimics, genetic medicines, and cell therapies. Its foundational offering is the ATX-Gx suite of fully humanized transgenic mouse platforms for antibody discovery, augmented by the Keyway TCRm platform, AntiClastic antisense oligonucleotide platform, iCAR-T cell therapy platform, and mAbForge high-throughput screening services. The company also operates the 82VS venture studio, which creates asset-centric biotech companies that leverage Alloy's platforms.

Product overview

Alloy Therapeutics operates as a biotechnology ecosystem company offering an integrated platform of drug discovery technologies and services across multiple modalities: antibodies, bispecifics, TCR mimics, genetic medicines, and cell therapies. The core offering is the ATX-Gx™ transgenic mouse platform for fully human antibody discovery, available through licensing (ATX-GK, ATX-GL, ATX-GKH) and service delivery (ATX-CLC). This foundation is augmented by mAbForge™ high-throughput screening services, the Keyway™ TCRm discovery platform for intracellular targets, the AntiClastic™ ASO platform for antisense oligonucleotides, and the iCAR-T platform for cell therapies. AI/ML capabilities including Deep Repertoire Intelligence, generative design, and predictive developability are embedded across discovery workflows. The company also provides Alloy Precision Pharmacology services and recently launched the Vigilance Division for biosecurity applications. All services are accessible through flexible licensing models and collaborative partnership approaches, with the venture studio 82VS enabling company creation.

Differentiator

Problem solved

Functional benefit

Brands

• 82VS: Venture studio that creates asset-centric biotech companies leveraging Alloy's platforms and services
• Spannerwerks
• Alloy Precision
• Alloy Cell Therapies
• Alloy Genetic Medicines

Products and services

• ATX-Gx Platform
• mAbForge High-Throughput Screening Service
• Keyway TCR Discovery Platform
• AntiClastic ASO Platform
• iCAR-T Cell Therapy Platform
• Monoclonal Antibody Discovery Services
• Bispecific Antibody Discovery Services
• Antibody Optimization Services
• Alloy Precision Pharmacology
• 82VS Venture Studio

Quantifiable outcome

• Over 200 partners and 100+ licensed therapeutic programs with 22 in clinical development
• +5 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Partnerships

19 partnerships are on record, tiered core, flagship, regional and ecosystem.

• Voro TherapeuticscoreStrategic or Co-development Partner · 18 June 2026Strategic research collaboration for next-generation masked T-cell engager therapeutics. Combines Voro's PrimeBody tumor-activated biologics platform with Alloy's optimized CD3 antibodies and multispecific engineering expertise.
• Institute for Protein Innovation (IPI)coreStrategic or Co-development Partner · 5 May 2026Strategic collaboration to create synthetic humanized VHH nanobody libraries for next-generation antibody discovery. Combines Alloy's integrated drug discovery infrastructure with IPI's protein engineering and in vitro platforms for bispecific and multispecific therapeutics.
• Cant ai TherapeuticscoreStrategic or Co-development Partner · 5 May 2026Partnership to develop bispecific antibodies for autoimmune disease using design-first approach integrating biological activity with developability and manufacturability requirements. Portfolio company of 82VS venture studio.
• BiogenflagshipStrategic or Co-development Partner · 7 April 2026Multi-target collaboration and license agreement for Alloy's AntiClastic ASO platform to advance antisense therapeutics against multiple undisclosed targets. Alloy receives upfront payment plus milestone payments and tiered royalties. Builds on prior collaboration including Biogen's use of Alloy's AI-enabled transgenic mouse platform.
• AbbVieflagshipStrategic or Co-development Partner · 17 March 2026Multi-year agreement to develop new antibody discovery platform targeting difficult-to-address therapeutic areas. Grants AbbVie access to Alloy's ATX-Gx platform with upfront and platform delivery payments.
• Mediar TherapeuticscoreStrategic or Co-development Partner · 3 February 2026Antibody discovery collaboration successfully completed using ATX-Gx transgenic mouse platform and AI/ML-enabled workflows to deliver differentiated antibodies against challenging fibrosis target, accelerating development timeline by six months.
• Tahoe TherapeuticscoreStrategic or Co-development Partner · 13 January 2026Joint venture to develop first-in-class antibody-drug conjugates for hard-to-treat cancers. Tahoe contributes AI-powered Mosaic platform for tumor targets; Alloy provides ADC engineering platforms and 82VS venture studio infrastructure.
• Swiss Rockets/Torpedo PharmaceuticalscoreStrategic or Co-development Partner · 12 January 2026Master Research Agreement for multi-target collaboration to discover and develop next-generation radioligand therapeutics for oncology using Terbium-161. Alloy provides antibody discovery and engineering platforms; Torpedo contributes radioisotope and radiopharmaceutical expertise.
• SpannerwerkscoreStrategic or Co-development Partner · 23 October 2025Acquisition of Spannerwerks, a Seattle-based drug development services firm, expanding Alloy's capabilities into drug development and enabling support through discovery to clinical development stages. CEO Dara Lockert leads Spannerwerks as part of Alloy ecosystem.
• University of British ColumbiacoreStrategic or Co-development Partner · 7 October 2025Collaboration to accelerate antibody discovery for pandemic preparedness using high-throughput cryo-electron microscopy technology under Canada's PROGENITER program. Alloy established subsidiary in Ontario, Canada as part of expansion.
• Kansai Startup Academia Coalition (KSAC)regionalStrategic or Co-development Partner · 22 July 2025Three-year MOU to collaborate on accelerating global expansion of university-affiliated life science startups across Japan. Alloy Japan supports KSAC's GAP Fund program and connects Japanese academic research to global biopharma markets.
• Republic of Serbia / BIO4 CampusregionalStrategic or Co-development Partner · 15 July 2025MOU to advance global bioeconomy by expanding access to drug discovery platforms and accelerating biotech startups in Serbia. Collaboration anchored at BIO4 Campus (opening 2027) with 1,000+ PhD scientists from 16 academic institutions.
• MultiOmic HealthcoreStrategic or Co-development Partner · 2 April 2025MOU to jointly discover and develop first-in-class renal tissue-targeting drugs. Alloy's bispecific antibody and genetic medicine platforms combined with MOH's AI-enabled patient stratification platform. New company RenalDevCo established through 82VS.
• Wheeler BioecosystemStrategic or Co-development Partner · 21 March 2025Preferred service offering for Alloy partners to accelerate translation from discovery to CMC. Wheeler Bio's modular CMC approach and PhaseTM offering provides preferred services including seamless discovery-to-IND transition.
• PfizerflagshipStrategic or Co-development Partner · 11 February 2025Multi-year collaboration to develop new antibody discovery platform enhancing Pfizer's ability to discover potent antibodies against challenging high-value targets. Builds on existing relationship including ATX-CLC common light chain platform launched in 2023.
• SanofiflagshipStrategic or Co-development Partner · 7 January 2025Target-specific collaboration for AntiClastic antisense platform targeting a central nervous system condition. Sanofi provides upfront and preclinical milestone payments up to $27.5M with potential discovery, development, and commercial milestones exceeding $400M plus tiered royalties on product sales.
• TakedaflagshipStrategic or Co-development Partner · 21 November 2024Collaboration and license agreement to develop iPSC-derived CAR-T and CAR-NK cell platforms for cancer therapies. Alloy gains co-exclusive rights to commercialize products. Joint effort aims to advance platforms from discovery to clinical development and improve access for biotech and pharma partners.
• Scripps ResearchcoreStrategic or Co-development Partner · 29 October 2024Non-exclusive institutional licensing agreement granting all Scripps Research scientists access to ATX-Gx platform for fully human antibody discovery and vaccine development.
• deepCDR BiologicscoreStrategic or Co-development Partner · 9 December 2021Acquisition of deepCDR Biologics, a Basel-based company specializing in deep learning for antibody discovery. Integration of bioinformatics and machine learning technologies into Alloy's services with expansion of Basel research facilities. Simon Friedensohn and Cédric Weber, co-founders of deepCDR, now lead Alloy's Insights division.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Adimab: Adimab is a direct peer offering yeast display-based antibody discovery platforms to biopharma partners. It is the historically dominant fully-human antibody discovery platform and shares founder Errik Anderson with Alloy Therapeutics, making it the most structurally comparable peer in product, business model (platform licensing + services), and customer base.
• AbCellera Biologics: AbCellera is a direct peer operating an antibody discovery platform that partners with pharma to discover therapeutic antibodies, including against challenging targets. Comparable to Alloy in its platform-licensing-plus-services model, multi-modality expansion (into T cell engagers), and reliance on milestone/royalty economics from partnered programs.
• Harbour BioMed: Harbour BioMed is a direct peer offering transgenic mouse (H2L2, HCAb) and single-domain antibody discovery platforms for licensing and partner collaborations. Comparable to Alloy in providing both platform IP and end-to-end discovery services to biopharma, with a similar tier of enterprise pharma customers.

Broad incumbents

• Twist Bioscience: Twist Bioscience is a broader incumbent offering synthetic DNA and antibody discovery services, including an antibody optimization platform and biopharma partnerships. Comparable to Alloy in offering synthetic biology-enabled antibody discovery at scale, though DNA synthesis is its core focus rather than transgenic animals.
• GenScript ProBio: GenScript ProBio is a broader-incumbent biologics CRO/CDMO offering antibody discovery, cell therapy, and gene therapy services. Comparable to Alloy in providing end-to-end biologics discovery and development across modalities, with similar pharma clients seeking integrated services.
• Charles River Laboratories: Charles River Laboratories is a broader-incumbent CRO offering antibody discovery and development services (including the acquired Distributed Bio platform). Comparable to Alloy in serving pharma and biotech partners with discovery and preclinical capabilities, though as a much larger and more diversified CRO.
• WuXi Biologics: WuXi Biologics is a broader-incumbent biologics CRO/CDMO providing antibody discovery, development, and manufacturing services. Comparable to Alloy at the level of multi-modality biologics platforms for global biopharma, though WuXi operates at substantially larger scale and is heavily focused on manufacturing rather than transgenic-based discovery.
• Distributed Bio (Charles River): Originally an independent antibody discovery platform using next-generation sequencing and computational biology, Distributed Bio was acquired by Charles River Laboratories in 2021. It is comparable to Alloy's Deep Repertoire Intelligence and SmartSelect NGS-informed antibody discovery offerings, and now competes as part of a much larger CRO portfolio.

Emerging players

• Compass Therapeutics: Compass Therapeutics is an emerging clinical-stage biotech with an antibody discovery pipeline that emerged from the same biotech ecosystem (Errik Anderson co-founded). Comparable to Alloy in originating from antibody platform roots, though Compass has internalized its discovery engine to develop proprietary clinical assets rather than licensing its technology.
• Atreca: Atreca is an emerging biotech with a differentiated antibody discovery platform built on immune-repertoire analysis. Comparable to Alloy in applying NGS/AI to antibody discovery and partnering with pharma, though Atreca focuses on oncology internal pipeline rather than broad partner licensing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alloy-therapeutics-inc
• Xx.com/alloytx

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries5 records

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alloy Therapeutics